Cargando…
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated
Low frequency of durable responses in patients treated with immune checkpoint inhibitors (ICIs) demands for taking complementary strategies in order to boost immune responses against cancer. Transforming growth factor‐β (TGF‐β) is a multi‐tasking cytokine that is frequently expressed in tumours and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889687/ https://www.ncbi.nlm.nih.gov/pubmed/36625080 http://dx.doi.org/10.1111/jcmm.17666 |
_version_ | 1784880785802657792 |
---|---|
author | Mortezaee, Keywan Majidpoor, Jamal |
author_facet | Mortezaee, Keywan Majidpoor, Jamal |
author_sort | Mortezaee, Keywan |
collection | PubMed |
description | Low frequency of durable responses in patients treated with immune checkpoint inhibitors (ICIs) demands for taking complementary strategies in order to boost immune responses against cancer. Transforming growth factor‐β (TGF‐β) is a multi‐tasking cytokine that is frequently expressed in tumours and acts as a critical promoter of tumour hallmarks. TGF‐β promotes an immunosuppressive tumour microenvironment (TME) and defines a bypass mechanism to the ICI therapy. A number of cells within the stroma of tumour are influenced from TGF‐β activity. There is also evidence of a relation between TGF‐β with programmed death‐ligand 1 (PD‐L1) expression within TME, and it influences the efficacy of anti‐programmed death‐1 receptor (PD‐1) or anti‐PD‐L1 therapy. Combination of TGF‐β inhibitors with anti‐PD(L)1 has come to the promising outcomes, and clinical trials are under way in order to use agents with bifunctional capacity and fusion proteins for bonding TGF‐β traps with anti‐PD‐L1 antibodies aiming at reinvigorating immune responses and promoting persistent responses against advanced stage cancers, especially tumours with immunologically cold ecosystem. |
format | Online Article Text |
id | pubmed-9889687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98896872023-02-02 Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated Mortezaee, Keywan Majidpoor, Jamal J Cell Mol Med Reviews Low frequency of durable responses in patients treated with immune checkpoint inhibitors (ICIs) demands for taking complementary strategies in order to boost immune responses against cancer. Transforming growth factor‐β (TGF‐β) is a multi‐tasking cytokine that is frequently expressed in tumours and acts as a critical promoter of tumour hallmarks. TGF‐β promotes an immunosuppressive tumour microenvironment (TME) and defines a bypass mechanism to the ICI therapy. A number of cells within the stroma of tumour are influenced from TGF‐β activity. There is also evidence of a relation between TGF‐β with programmed death‐ligand 1 (PD‐L1) expression within TME, and it influences the efficacy of anti‐programmed death‐1 receptor (PD‐1) or anti‐PD‐L1 therapy. Combination of TGF‐β inhibitors with anti‐PD(L)1 has come to the promising outcomes, and clinical trials are under way in order to use agents with bifunctional capacity and fusion proteins for bonding TGF‐β traps with anti‐PD‐L1 antibodies aiming at reinvigorating immune responses and promoting persistent responses against advanced stage cancers, especially tumours with immunologically cold ecosystem. John Wiley and Sons Inc. 2023-01-10 /pmc/articles/PMC9889687/ /pubmed/36625080 http://dx.doi.org/10.1111/jcmm.17666 Text en © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Mortezaee, Keywan Majidpoor, Jamal Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated |
title | Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated |
title_full | Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated |
title_fullStr | Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated |
title_full_unstemmed | Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated |
title_short | Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated |
title_sort | transforming growth factor‐β signalling in tumour resistance to the anti‐pd‐(l)1 therapy: updated |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889687/ https://www.ncbi.nlm.nih.gov/pubmed/36625080 http://dx.doi.org/10.1111/jcmm.17666 |
work_keys_str_mv | AT mortezaeekeywan transforminggrowthfactorbsignallingintumourresistancetotheantipdl1therapyupdated AT majidpoorjamal transforminggrowthfactorbsignallingintumourresistancetotheantipdl1therapyupdated |